Chemistry:STC3141
STC3141 is an extracellular histone neutralizer which is under development for the treatment of sepsis and COVID-19 pneumonia.[1][2][3][4][5][6] It is given by intravenous infusion.[1][4] The drug is a carbohydrate-based polyanion molecule of β-O-methyl cellobiose sulfate sodium salt (mCBS.Na).[3][5][6] It may limit inflammation and organ damage in sepsis by blocking toxic circulating histones in the condition.[6][4] Accordingly, the drug showed preliminary efficacy in reducing sepsis in a phase 2 clinical trial.[6] STC3141 was developed by Griffith University and the Australian National University and is under development by Grand Pharmaceutical Group in China.[1][6] As of January 2026, it is in phase 2 trials, with a phase 3 trial being planned.[1][2][6]
References
- ↑ 1.0 1.1 1.2 1.3 "STC 314". 15 May 2025. https://adisinsight.springer.com/drugs/800058769.
- ↑ 2.0 2.1 "Delving into the Latest Updates on STC3141 with Synapse". 16 May 2025. https://synapse.patsnap.com/drug/d7e77b9f144940e48fe8434da093c8ab.
- ↑ 3.0 3.1 "STC3141 improves acute lung injury through neutralizing circulating histone in rat with experimentally-induced acute respiratory distress syndrome". Frontiers in Pharmacology 14. 2023. doi:10.3389/fphar.2023.1166814. PMID 37284312.
- ↑ 4.0 4.1 4.2 "A dose-adjusted, open-label, pilot study of the safety, tolerability, and pharmacokinetics of STC3141 in critically ill patients with sepsis". Pharmacology Research & Perspectives 12 (5). October 2024. doi:10.1002/prp2.70015. PMID 39401149.
- ↑ 5.0 5.1 "Neutralizing the pathological effects of extracellular histones with small polyanions". Nature Communications 11 (1). December 2020. doi:10.1038/s41467-020-20231-y. PMID 33328478. Bibcode: 2020NatCo..11.6408M.
- ↑ 6.0 6.1 6.2 6.3 6.4 6.5 "Researchers May Have Unlocked the Secret to Treating Sepsis". 21 January 2026. https://scitechdaily.com/researchers-may-have-unlocked-the-secret-to-treating-sepsis/.
 |  |
